The Zinc Ionophore Clioquinol Reduces Parkinson’s Disease Patient-Derived Brain Extracts-Induced Neurodegeneration

• Published in: Molecular neurobiology Vol. 59; no. 10; pp. 6245 - 6259
• Main Authors: Teil, Margaux, Doudnikoff, Evelyne, Thiolat, Marie-Laure, Bohic, Sylvain, Bezard, Erwan, Dehay, Benjamin
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.10.2022; Springer Nature B.V; Humana Press
• Subjects: Autophagy; Biomedical and Life Sciences; Biomedicine; Cell Biology; Cellular Biology; Chelation; Clioquinol; Cytotoxicity; Diet; Dopamine receptors; Heavy metals; Intracellular; Lewy bodies; Life Sciences; Movement disorders; Neostriatum; Neurobiology; Neurodegeneration; Neurodegenerative diseases; Neurology; Neurosciences; Parkinson's disease; Patients; Subcellular Processes; Substantia nigra; Synuclein; Zinc; α-Synuclein; Clioquinol; Parkinson’s disease; Zinc
• ISSN: 0893-7648; 1559-1182
• DOI: 10.1007/s12035-022-02974-5

Parkinson’s disease (PD) is pathologically characterized by intracellular α-synuclein-rich protein aggregates, named Lewy bodies (LB), and by the progressive loss of dopaminergic neurons in the substantia nigra. Several heavy metals, including zinc (Zn), have been suggested to play a role in PD progression, although the exact role of Zn in neurodegeneration remains to be fully elucidated. To address this gap, we investigated the effects of Zn modulation on the progression of degeneration in mice injected with PD patient-derived LB-extracts carrying toxic α-synuclein aggregates. Zn modulation was achieved using either a clioquinol-enriched diet, a Zn ionophore that redistributes cellular Zn, or a Zn-enriched diet that increases Zn levels. Clioquinol treatment significantly prevented dopaminergic neurodegeneration and reduced α-synuclein-associated pathology in LB-injected mice, while no differences were observed with Zn supplementation. Biochemical analyses further demonstrate that the expression levels of vesicle-specific Zn transporter ZnT3 in the striatum of LB-injected mice treated with clioquinol were decreased, suggesting an intracellular redistribution of Zn. Additionally, we found that clioquinol modulates the autophagy-lysosomal pathway by enhancing lysosomal redistribution within the neuronal compartments. Collectively, we found that in vivo pharmacological chelation of Zn, by dampening Zn-mediated cytotoxicity, can result in an overall attenuation of PD-linked lysosomal alterations and dopaminergic neurodegeneration. The results support zinc chelation as a disease-modifying strategy for treating PD.